Ken Getz, the founder of CenterWatch—a clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information. The acquisition was completed in April.
Getz founded CenterWatch in 1994 and established the company as a provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. CenterWatch was subsequently sold to Jobson Medical Information in 2007.
“I am very excited to have CenterWatch back,” said Getz. “We have plans to modify and improve our print- and web-based publications and services while adding new offerings to assist investigative sites, pharmaceutical and biotechnology companies, contract research organizations and other service providers in being better informed, more effective and successful.”
The May issue of The CenterWatch Monthly newsletter features results and analysis of the 2010 Survey of Investigative Sites in Europe.
Getz is the Chairman of CISCRP—a nonprofit organization that he founded to educate and raise public awareness of the clinical research enterprise—and a Senior Research Fellow at the Tufts Center for the Study of Drug Development where he studies R&D management and operating models, investigative site, outsourcing, and study volunteer trends and policies.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.